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Autoantibodies directed at the intracellular Ro ribonucleoprotein complex are found in the
serum ofpatients with systemic lupus erythematosus (SLE) and related autoimmune diseases.
The antigenic stimulus for the induction ofthese autoantibodies is unknown, although we have
previously demonstrated that the Ro protein and immunoglobulin G (IgG) share immunologic
determinants boundby anti-Ro antibodies. The present studyfurther defines the fine specificity
of this cross-reactive binding. Using both patient autoanti-Ro antibodies and antigen-induced
rabbit anti-Ro serum, the binding specificity for IgG was located to the heavy chains of IgG
outside the Fc domain. F(ab')2fragments ofIgG were observed to inhibit specific Robindingby
either human or antigen-induced rabbit sera, while Fc fragments of IgG failed to inhibit Ro
binding. Anti-Ro sera were found to bind the heavy chains of IgG in immunoblots, and the
antibodies eluted from these heavychainswere capable ofimmunoprecipitating the Roparticle
from human cell extracts. Not all patient sera with anti-Ro antibodies possessed IgG binding
antibodies. Studies ofcyanogen bromide digestion fragments ofIgG implicate the hinge region
of IgG as the region cross-reactive with the Ro protein. The nature ofthis cross-reactivity may
be important in understanding the induction and/or perpetuation of the anti-Ro response in
patientswith autoimmune disease.
INTRODUCTION
The presence of serum autoantibodies to a wide variety ofcellular constituents is
an underlying theme in patients with connective tissue disease. In particular,
autoantibodies directed at nucleic acids and at proteins which bind both DNA and
RNA are diagnostic markers for patients with systemic lupus erythematosus [1].
These autoantibodies commonly include specificities for the Sm, Ul(nRNP), Ro,
and La ribonucleoproteins [1]. Autoantibodies specific for the intracellular RNA-
protein complex designated "Ro" are observed in over halfofpatients with systemic
lupus erythematosus (SLE), most patients with Sjogren's syndrome, and a substan-
tial percentage of normal individuals [2,3]. The exact biological function of the Ro
ribonucleoprotein is unknown, though its role as an important target in autoimmune
responses has been known since the first description of this autoantibody by
Anderson et al. in 1961 [4].
The Ro protein is associated with two to four uridine-rich RNAs, depending both
on the species of mammalian cell and the type of somatic cell examined [5,6]. In
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humans, the Ro RNAs are from 83 to 112 nucleotides in length and are a product of
RNA polymerase III in the cell. The Ro protein is also transiently associated on
RNAswith another ribonucleoprotein designated "La," and autoantibodies to these
two ribonucleoproteins are frequently co-expressed in patient sera [7]. The Ro
protein and its RNAs are precipitable from several mammalian species by patient
sera, suggesting that manyofthe autoantigenic epitopes ofthe protein are evolution-
arily conserved [6].
In a previous study, we have shown that anti-Ro antibody from both autoimmune
patient serum and antigen-induced animal serum bind not only the Ro protein but
also have IgG binding activity [8]. Consistent with this observation, it has been
reported that 70 percent ofpatients with Ro precipitating autoantibodies also have
rheumatoid factors [9]. It may be postulated, therefore, that the anti-Ro component
of sera may contribute to the detection ofpositive rheumatoid factors. In this study,
we have analyzed the fine specificity of anti-Ro antibody for the IgG molecule. We
conclude that the IgG cross-reactivity of anti-Ro does not resemble conventional
rheumatoid factors, since Fc regions ofIgG are not bound by anti-Ro. We have now
demonstrated that the anti-Ro antibody has binding specificity for the F(ab')2 heavy
chain region of IgG. The dual specificity of binding by anti-Ro autoantibodies may
help to explain how the autoantibody response isfirst initiated orhowthe response is
maintained in patients with systemic autoimmune disease.
METHODS
Punification ofRoProtein
Bovine Ro protein was purified according to a previously'reported procedure [10].
Briefly, bovine spleen was cut into two cm2 pieces and mixed with an equal amount
(weight/volume) of PBS with 2 mM dithiothreitol. The mixture was homogenized,
centrifuged at 10,000g, and the supernatant ofthis cell lysate was incubated with 40
percent (volume/volume) DE-52 (Whatman Co., Clifton, NJ) for four hours at 4°C
with occasional stirring. The DE-52 was thoroughly washed with PBS and extracted
with 1.0 M NaCl in 0.02 M phosphate buffer, pH 7.2. The extract was then run
through an affinity column made from the IgG fraction of a patient serum with high
titers ofanti-Roantibody. The columnwaswashed and elutedwith 3.0 M MgCl2, and
the eluate was dialyzed against 0.02 M Tris, 0.15 M NaCl, pH 7.2 (TBS). Ro protein
purified by this method consists of a single characteristic 60 kD band by SDS-PAGE
and is free ofcontaminating IgG or other related ribonucleoproteins [8].
Isolation ofIgGBindingFractionsfromAnti-Ro Sera
Rabbit anti-Ro antibodies were generated by immunization and subsequent
boosts with affinity-purified 60 kDa Ro protein, as previously described [6]. The IgG
binding components of either human or rabbit anti-Ro serum were purified by
affinity chromatography. Rabbit or human anti-Ro and normal human and rabbit
sera as controls were adsorbed to affinity columns consisting of Cohn fraction V of
normal human IgG (Sigma Chemical Co., St. Louis, MO), attached to cyanogen
bromide-activated Sepharose 4B. The columns were extensively washed with TBS
and eluted with 3 M MgCl2. The fractions were dialyzed against TBS, concentrated
(Amicon Co., Danvers, MA), and studied for their Ro and IgGbindingproperties, as
described below.
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Westem Immunoblots andElution ofAntibodyfrom IgG Heavy andLight Chains
Blotting of human IgG substrates was performed by established techniques [11].
Briefly, human IgG (Sigma) was run under denaturing conditions in 7.5 percent
(weight/volume) polyacrylamide gels and electrophoretically transferred to nitrocel-
lulose (Bio-Rad, Richmond, CA). The nitrocellulose was blocked in 1 percent BSA
and probed with a 10-2 dilution ofrabbit anti-Ro or pre-immune rabbit serum. Goat
anti-rabbit alkaline phosphatase conjugate was incubated with nitrocellulose and
developed with ,-naphthyl acid phosphate and o-diansidine, as previously described
[12].
Alternatively, antibodies were eluted from the heavy or light chains of IgG [13].
Human IgG was electrophoresed in reducing PAGEgels and transferred to nitrocel-
lulose. Human and rabbit anti-Ro (10-2 dilutions) were incubated with the blot, and
the heavy and light chains of IgG were each cut from the nitrocellulose. Antibodies
were twice eluted from the nitrocellulose strips with 15 mM glycine, 0.5 M NaCl, 0.1
percent Tween, and 100 pug/ml BSA (pH 2.3) for two minutes. Eluted antibody was
immediatelyneutralized topH 7.2with 1.0 MTris, pH 8.0. Antibodies eluted in these
fractions were then used in the RNA immunoprecipitation assay.
Immunoprecipitation ofRo RNAs
The RNAs associated with the Ro protein were immunoprecipitated as previously
reported [14]. HeLa cell stocks were maintained at 37°C, 5 percent CO2 in RPMI
1640 (Gibco Laboratories, Grand Island, NY), supplemented with 10 percent fetal
calf serum, 60 iig/ml penicillin, and 100 ,ug/ml streptomycin. Log phase Hela cells
were centrifuged (400g, five minutes), washed once with' TBS, and resuspended to
2 x 105 cells/ml in phosphate-free minimal essential medium (Gibco), supplemented
with 10 ,uCi/ml 32p orthophosphate (Amersham, Arlington Heights, IL). After 16
hours (37°C, 5 percent C02), the cellswerewashedwith TBS, resuspended in NET-2
buffer (50 mM Tris, 150 mM NaCl, 0.05 percent NP-40, pH 7.4), and sonicated. The
cell sonicate wascentrifuged at 10,OOOgfor30minutes, and the lysatewas mixedwith
protein A-Sepharose 4B (Pharmacia Co., Piscataway, NJ), bound to rabbit anti-Ro
or affinity-purified IgG binding fractions of the rabbit sera. After 60 minutes, the
samples were washed five times with NET-2 and deproteinized with phenol/
chloroform/isoamyl alcohol (50:50:1). The aqueous layer was removed, and the
nucleic acids were precipitated with 100 percent cold ethanol. The samples were
denatured at 65°C for three minutes in sample buffer (10 M urea, 0.025 percent
bromophenol blue, and 0.025 percent xylenecyanol FF in Tris-borate EDTA buffer
[90 mM Tris, 90 mM borate, 1 mM EDTA, pH 8.6]) and electrophoresed in a 7 M
urea/10 percent polyacrylamide gel. The gel was dried and exposed to photographic
film (Eastman Kodak Co., Rochester, NY) against an intensifying screen for 20 hours
at -70°C.
Enzyme-Linked ImmunosorbentAssays (ELISA)
Twenty SLE patient sera positive for anti-Ro in immunodiffusion studies and
negative for rheumatoid factor by latex fixation were examined for binding to
purified Ro, F(ab')2, and Fc fragments of IgG by ELISA, according to established
methods [10,15]. Purified human F(ab')2 and Fc fragments (Cappel Laboratories,
Malvern, PA) were adsorbed tomicrotiter plates at 10 ,ug/ml in carbonate buffer, pH
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FIG. 1. Western immunoblot ofpurified Ro pro-
1 2 3 4 5 6 teinandhumanIgGwithrabbitanti-Ro. Purified60
* _ ]_ kDa Ro protein (lanes 2,4, and 6) and human IgG
60 kDa
- (lanes 1,3, and 5) were run in reducing SDS-PAGE
50 kDa
- gels and transferred to nitrocellulose. Blots were
probed with rabbit anti-Ro serum (lanes 1 and 2),
the rabbit anti-Ro serum fraction eluted from hu-
man IgG affinity columns (lanes 3 and 4), or pre-
immune rabbit serum (lanes5 and6).
9.6. Purified Ro was similarly plated at 5 ,ug/ml. Plates were blocked with 1 percent
bovine serum albumin (BSA), and 10-2 serum dilutions ofpatient sera were applied
to duplicate wells for two hours at room temperature. The plates were washed, and
the F(ab')2-coated plates were incubated with anti-human Fc conjugated to alkaline
phosphatase (Sigma). Conversely, the Ro- and Fc-coated plates were incubated with
anti-human F(ab')2 conjugate. After thorough washing and the addition of p-nitro-
phenylphosphate substrate, the optical density was measured at 405 nm (MR 580
ELISA reader, Dynatec Laboratories, Alexandria, VA).
Fragments of human IgG and purified Ro protein were investigated for their
ability to inhibit Ro binding activity of human and rabbit anti-Ro serum. The IgG
fraction of a prototype human anti-Ro serum was biotinylated by the method of
Wofsy [16]. Rabbit anti-Ro andbiotinylated human anti-Ro were pre-incubatedwith
100 ,ug/ml of human F(ab')2, Fc, whole IgG, or 10 p,g/ml purified Ro protein.
Samples were applied to Ro-coated plates, and binding was detected with goat
anti-rabbit IgG-alkaline phosphatase (Sigma) or avidin-alkaline phosphatase, as
described above (Sigma). All data represent the mean of duplicate wells from
representative experiments.
Cyanogen Bromide Cleavage ofIgG
Specific fragments of the IgG molecule were obtained by cyanogen bromide
(CNBr) digestion, according to previously described methods [17,18]. Pooled human
IgG was dissolved in 70 percent formic acid to a concentration of 20 mg/ml. Solid
CNBr was added 5:1 (weight/weight), and the reaction mixture was incubated 24
hours at room temperature. The contents were brought up in ten volumes of water
and lyophilized to stop the reaction. Fragments were isolated by fast protein liquid
chromatography (FPLC) (Pharmacia) over a Superose 12 gel filtration column
(Pharmacia) with 0.1 M acetic acid as running buffer. Sample peaks collected from
the FPLCwere analyzed for molecular weight bycomparison ofretention times with
standard molecular weight markers (Bio-Rad), run under identical conditions. Peak
fractions were then adsorbed to microtiter plates in PBS for ELISA binding analysis
ofrabbit anti-Ro sera, as described above.
RESULTS
Antibody Elutedfrom IgGBinds the Ro Ribonucleoprotein
IgG binding antibodies were obtained first by immunoaffinity purification on
human IgG-Sepharose 4B. Both whole rabbit serum (Fig. 1, lanes 1 and 2) and the
rabbit serum fraction elutedfrom the IgG affinity column immunoblotted the 60 kDa
purified Ro protein (lanes 3 and 4) as well as the 50 kDa heavy chain of human IgG.
The sera failed to bind the light chains of IgG in immunoblots, and pre-immune
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FIG. 2. Immunoprecipitation of human Ro
RNAs. Fractions of rabbit anti-Ro serum were
used toimmunoprecipitate ribonucleoprotein par-
ticles from 32P-labeled HeLacell extracts. Lane 1,
total HeLa cell RNA; lane 2, pre-immune rabbit
serum; lane 3, rabbit anti-Ro whole serum; lane
4, rabbit anti-Ro serum fraction eluted from a
human IgG affinity column; lane5, rabbit anti-Ro
eluted from the light chains of human IgG; lane
6, rabbit anti-Ro eluted from the heavy chains of
human IgG.
rabbit serum failed to bind either purified Ro protein or the heavy or light chains of
IgG (lanes 5 and 6). These results support our previous study that demonstrated
binding to Ro protein in solid phase immunoassays by antibodies eluted from
IgG-Sepharose affinity columns [8].
The IgG eluates were then used to immunoprecipitate the Ro particle from
32P-labeled Hela cells in order to determine if the shared antibody binding site
between Ro and IgG is present on the native Ro particle (Fig. 2). Total ethanol-
precipitated RNA from Hela cell extracts is shown in lane 1. The Ro RNAs are not
detectable in total RNA extracts from cell lysates because of their low copy number
in the cell. Pre-immune serum failed to precipitate Ro RNAs (lane 2), while rabbit
anti-Ro whole serum immunoprecipitated the typical Ro RNAs designated hYl to
hY5 (lane 3). Rabbit anti-Ro antibody eluted from the human IgG affinity column
also precipitated the Ro RNAs (lane 4).
Rabbit anti-Ro was eluted from the heavy and light chains of IgG in Western
immunoblots, as described above. Elution steps from the light chains ofIgG failed to
precipitate the Ro RNAs (Fig. 2, lane 5), while antibody eluted from heavy chains
weakly precipitated the typical Ro RNAs (lane 6). Antibody eluted from the heavy
chains is therefore capable ofbinding the native Ro particle from crude cell extracts.
As further controls, anti-Sm human sera were adsorbed to IgG blots and eluted as
above. All elutions failed to immunoprecipitate the typical Sm RNAs from HeLa cell
extracts (data not shown).
Anti-Ro Preferentially Binds F(ab')2andHeavy Chain Fragments ofIgG
In attempts to localize the IgG binding site of anti-Ro antibodies, 20 patient sera
with anti-Ro were screened in solid phase assays for Fc or F(ab')2 fragment binding
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activity (Fig. 3). All sera examined were negative for rheumatoid factors by conven-
tional latex agglutination assays. When purified human Fc fragments were adsorbed
to microtiter plates, anti-human F(ab')2-specific enzyme conjugate was used to
detect patient IgG binding. Conversely, when human F(ab')2 fragments were the
source of antigen, anti-human Fc-specific conjugates were used to detect patient
antibody. Purified human Fc, F(ab')2, and bovine Ro were all plated at 5 ,ug/ml.
Patient sera were tested at 10-2 dilutions for binding to fractions of IgG and at 10-3
serum dilutions for Ro protein binding. For all sera examined, relative Ro binding
O.D. 405 was greatest when compared to their respective Fc or F(ab')2 binding
activity. All seradisplayedweakFcbinding relative tonormal serumcontrols. Twelve
of 20 sera showed significant binding (>2 S.D. above the mean of normal serum
controls) to the F(ab')2 fragments of human IgG. Twenty sera specific for the Sm
and/or Ul autoantigens by immunodiffusion failed to bind significantly the Fc,
F(ab')2, or Ro protein antigens in this solid phase assay by the above criterion (data
not shown).
Inhibition ofRoBindingbyFragments ofIgG
Purified Ro protein, purified IgG, and fragments thereof were examined in solid
phase assays for their ability to inhibit Ro binding activity (Table 1). Prototype
human anti-Ro was first biotinylated so that human IgG used in inhibition assays
would not interfere in the interpretation ofthe results. Purified Ro protein inhibitedANTI-RO AUTOANTIBODY BINDS IgG
TABLE 1
Human F(ab')2 and Fc Inhibition of Ro Binding Activity
% Inhibitiona
Ro Binding Whole
O.D. 405 F(ab')2 Fc IgG Ro
Human anti-Ro 0.34 48 7 34 83
Rabbit anti-Ro 0.69 41 18 61 94
aRabbit and biotinylated human anti-Rowere pre-incubated with 100 xLg/ml each ofhuman F(ab')2, Fc,
whole IgG, or 10 p.g/ml ofpurified Ro protein prior to their addition to Ro-coated plates. Percentage of
inhibition was calculated as: 1 - (inhibited O.D. 405/untreated O.D. 405) x 100. Normal human serum
and pre-immune rabbit serum background was <0.09 O.D. 405.
83 percent ofthe Ro binding activity. Fc fragments onlyweakly inhibited Ro binding
(7 percent) relative to inhibition by whole human IgG (34 percent) or F(ab')2
fragments (48 percent). Likewise, the rabbit anti-Ro serum was best inhibited by
purified Ro protein (94 percent). Fc fragments failed to inhibit Ro binding (18
percent) aswell as whole IgG (61 percent) or F(ab')2 fragments (41 percent).
Anti-RoAntibody Binding to Cyanogen Bromide-Digested Fragments ofIgG
In order to characterize further the binding site on IgG of the Ro binding
antibodies, CNBr-cleaved fragments of human IgG were assessed for antibody
binding in ELISA assays. Pooled human IgG was first completely digested with
cyanogen bromide in 70 percent formic acid and lyophilized. Fragments were
resuspended and separated by FPLC over agel filtration column. Five separate peak
fractions were obtained (Fig. 4), as previously observed by other investigators [18].
Fractionswere collected and adsorbed to the solid phase ofmicrotiter plates. Rabbit
anti-Ro whole serum and biotinylated human anti-Ro were assayed for binding to
the CNBr digestion fragments of human IgG (Table 2). Both human and rabbit
anti-Ro bound fraction 41 best among the fractions collected. Binding to fraction 41
by human or rabbit anti-Ro serum was significantly inhibited by pre-incubation with
purified Ro protein (82 percent and 68 percent, respectively; data not shown). The
molecularweight offraction 41 is approximately 10 kDawhen compared to standard
molecularweight markers forcolumncalibration. The CNBrprofiles obtained in this
study correspond to those obtained by gel filtration chromatography in previous
studies [17,18,20]. Although this peak was not identified by amino acid sequence
analysis, it does correspond identically to a CNBr digestion product of the hinge
region ofthe gamma chain ofIgG [18].
DISCUSSION
Our previous study had demonstrated that a subset of Ro binding autoantibodies
also bound human and bovine immunoglobulin G [8]. Initially, upon adsorption of
anti-Ro serum over IgG affinity columns, the relative specific Ro binding activity of
the effluent was dramatically decreased when compared to unadsorbed serum.
Furthermore, the eluates from these IgG columns retained Ro binding activity in
ELISAassays. The present studyextends ourpreviouswork [8] in order to character-
ize further the specificity of the IgG binding site by both human autoimmune serum
and heteroimmune rabbit anti-Ro antibodies. We have also surveyed the IgG
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FIG. 4. Fragments of cyanogen bromide-digested human IgG. Pooled human IgG was digested with
CNBr, and polypeptides were separated by FPLC over a gel filtration column. Fractions were collected for
the peaks as indicated. Retention ofmolecular weight standard markers (66 kDa, 45 kDa, 21 kDa, and 14
kDa) are indicated at the top ofthe figure.
binding activity from a series of human anti-Ro sera in order to understand the
prevalence ofthese cross-reactive antibodies.
Rabbit anti-Ro antibodies have been used in this and other studies of the 60 kDa
Ro ribonucleoprotein [6,8]. The use of antigen-induced animal serum in these
studies lends insight into the origins of patient autoantibodies, which arise from
undetermined origins. Our rabbit antibodies resemble human autoantibodies in a
number ofrespects. Both sera show identity for Ro in Ouchterlony immunodiffusion,
bind the 60 kDa Ro protein in immunoblots, and compete for Ro epitopes in solid
phase assays [6,8]. Both human and rabbit anti-Ro bind the native Ro particle, as
TABLE 2
Binding ofAnti-Ro to CNBr Fragments of IgG
Fractiona
7 16 20 24 30 41
Human anti-Ro .07 .18 .20 .28 .15 .64
Rabbit anti-Ro .09 .08 .11 .06 .12 .22
aCyanogen bromide fragments ofhuman IgG were isolated by FPLC (Fig. 4) and adsorbed to the solid
phase ofmicrotiterwells. Rabbit and prototype human anti-Ro serawere then tested for their ability to
bind the isolated fragments (O.D. 405). Non-immune sera had background binding of <0.11 for all
fractions.ANTI-RO AUTOANTIBODY BINDS IgG
shown by the ability to immunoprecipitate the Ro RNAs from human cell lysates
(Fig. 2). While it has been demonstrated recently that some human sera bind a
distinct 52 kDa Ro protein [19], the rabbit anti-Ro serum only precipitates the 60
kDa Ro protein. The rabbit serum serves as an excellent model of anti-Ro specifici-
ties, since it is a true autoantibody, as measured by its ability to bind autologous
rabbit Ro protein [8].
The rabbit anti-Ro serum binds both the 60 kDa Ro protein and 50 kDa heavy
chains of IgG in immunoblots (Fig. 1). Light chain binding is not apparent in these
studies. In addition, a prototype human anti-Ro serum binds the heavy chain of
bovine IgG in immunoblots (data not shown). Antibody eluted from the heavy chains
of IgG in these blots immunoprecipitates the Ro RNAs (Fig. 2), suggesting that the
cross-reactive epitope is present on both the native Ro particle and the reduced
heavy chain of IgG. The 52 kDa Ro protein does not possess the cross-reactive
epitope, since our sera do not bind this Ro protein. Our data support the initial
observation that the 52 kDa protein has epitopes different from those on the 60 kDa
Ro protein [19].
Binding to human Fc, F(ab')2, and purified Ro was assayed in a series of patient
sera with precipitin-positive anti-Ro antibodies. All sera bound Ro with at least
tenfold greater relative titers than either fragment of IgG (Fig. 3). No sera were
observed to bind Fc fragments significantly over normal human serum controls, while
12 of 20 sera bound F(ab')2 fragments in the ELISA assay. The Ro binding
antibodies in human and rabbit sera were also significantly inhibited by purified Ro
and human F(ab')2 fragments but not by Fc fragments (Table 1). This observation
suggests that the cross-reactive epitope lies on the heavychain outside the Fc domain
of IgG.
The IgG fragments derived from cyanogen bromide digestion have now been well
characterized [17,18,20]. We utilized these digests to confirm further the location of
the IgG epitope bound by anti-Ro sera. Cyanogen bromide digestion ofIgG yielded
four major peaks (Fig. 4). Polypeptides from fraction 41, the smallest polypeptides in
molecular weight among the peaks collected, were bound best by both human and
rabbit anti-Ro serum. The peak from fraction 41 corresponds to a molecular weight
of approximately 10 kDa that is consistent with a fragment of IgG, located at the
hinge region of the gamma heavy chain [20]. The region is rich in hydrophilic amino
acids, which may lend itselfto expression as an immunogenic region ofthe surface of
the IgG molecule.
Previous studies have demonstrated the presence ofautoantibodies specific for the
Fab and F(ab')2 fragments of IgG [21,22]. These autoantibodies are typically found
in patients with rheumatoid arthritis and systemic lupus erythematosus (SLE). The
co-expression of anti-Ro with anti-F(ab')2 in these patients may be related to the
expression of cross-reactive epitopes between the Ro particle and IgG, as described
in this study. Alternatively, these cross-reactive epitopes may be responsible for the
initiation and/or perpetuation ofthe autoantibody responses.
In evaluating the series of patient sera with precipitin-positive anti-Ro, the sera
with highest anti-Ro titers by ELISA also had the highest anti-F(ab')2 antibody
responses. Only one exception among this group was notable for relatively low
anti-Ro ELISA titers with measurable anti-F(ab')2 activity. Not surprisingly, it has
previously been reported that high titers of antinuclear antibodies and rheumatoid
factors contribute to anti-Ro precipitin formation in immunodiffusion studies [9].
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Our observations suggest that a subset of anti-Ro antibodies bind a cross-reactive
epitope of IgG. Not all precipitin-positive sera possessed IgG binding properties.
These cross-reactive antibodies are most likely to appear as the anti-Ro responses
mature and become high-titered in the patient.
Based on end point dilutions in ELISA, the antigen-induced rabbit serum had
relative anti-Ro titers as high as our prototype patient serum and also possessed the
cross-reactive idiotype. The animal model of anti-Ro antibody induction thus
resembles the human autoantibody and suggests that the anti-Ro response in
humans is induced by the 60 kDa Ro antigen itself.
Other antibodies with cross-reactive properties to IgG have been previously
described inpatientswith autoimmune disease [23-25]. Autoantibodieswith specific-
ity for histones and native DNA have been found to possess rheumatoid factor-like
activity. Binding to these multiple epitopeswas removed by adsorption to IgG,just as
anti-Ro binding is removed by IgG adsorption in our study. Amino acid sequence
studies of histone proteins reveal no similarities with IgG that would suggest a
structural analog for the existence of cross-reactive epitopes, just as the available
sequence ofthe human 60 kDa Ro protein does not demonstrate homologywith IgG
[26]. Indeed, amino acid sequence homology is not necessarily a requisite of im-
munologic cross-reactivity. The basis ofthe cross-reactivity between Ro and IgGwill
become more obvious as specific structural properties and studies of immunologic
determinants ofthe Ro protein become available.
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